Broadview Ventures, Inc
Broadview Ventures is a Boston based venture fund established in 2008 by the Leducq Family Trust.
About Broadview: "Broadview has as mission to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures. By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients".
Novo A/S is a lead investor in Acesion Pharma and invested in the company through Novo Seeds, the early stage investment arm of Novo A/S.
About Novo A/S: "Novo A/S is the holding company in the Novo Group and is responsible for the management of the assets of the Novo Nordisk Foundation. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets"
About SEED Capital: "SEED Capital is the largest venture fund in Denmark within the pre-seed and seed segment, and specializes in identifying and developing new and innovative technology companies. SEED Capital manages both private venture capital and public funds through innovation environment, Pre-SEED Innovation. SEED Capital manages approx. 1.5 billion DKK and has about 70 companies in its portfolio".
In 2013 UK based Wellcome Trust granted Acesion Pharma a Seeding Drug Discovery Strategic Award of 27.9 million DKK (3.7 million EUR) to fund Acesion Pharma's program aiming for an acute treatment of atrial fibrillation (AF).
About the Wellcome Trust: "the Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests".
Innovation Fund Denmark
In December 2013 Acesion Pharma received, in collaboration with University of Copenhagen, a grant of 14.4 million DKK from The Danish National Advanced Technology Foundation which in 2014 became part of the new Innovation Fund Denmark, established by the Danish government. Innovation Fund Denmark has as a goal to invest in new knowledge and technology creating growth and employment in Denmark.